Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Acute vaso-occlusive episodes (VOEs) in sickle cell disease (SCD) are primarily managed with
opioids. Tolerance and hyperalgesia to opioids develops due to N-methyl-D-aspartate
(NMDA)-receptor mediated activation of the nociceptive system, and as a receptor antagonist,
ketamine mitigates this. Intravenous (IV) ketamine has demonstrated efficacy in reducing
post-operative, chronic, and cancer-related pain in pediatrics, as well as in reducing time
to pain control in the emergency department (ED) in adults. Limited studies suggest efficacy
in adult opioid-refractory SCD patients. This study is investigating the safety and
tolerability of adjuvant low-dose IV ketamine bolus for pediatric SCD VOE in the ED, as well
as its efficacy in improving pain control and reducing hospitalization.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital & Research Center Oakland UCSF Benioff Children's Hospital Oakland